Was ist die Webseite?

Hanna Diabetes Expert

Startseite
Schweiz
Zürich
Hanna Diabetes Expert

As a patient leader, international speaker, and consultant, I’m passionate about improving patient centricity in health care.

I hold an MSc in Diabetes and has a background in nutrition and coaching. I’m a keynote speaker, author & researcher (too).

26/05/2026

Airports, time zones, airport/plane food, delays, security checks… and diabetes still expects a full-time employee. ✈️ 🫠

PSA, in life with diabetes there are no days off, no “vacation mode”, no autopilot. Just constant decisions in the background while trying to live life in the foreground.

At least the sunflower lanyard helps make the invisible a little more visible 🙏 🌻💙

13/05/2026

Last week’s Insulin Insights Conference 2026 was incredibly impactful. ✨

What a day.

After so many months of planning, discussions, problem-solving, preparation, and heart poured into this conference, it was incredibly rewarding to finally see it come to life (and even more meaningful to feel the atmosphere in the room throughout the day.)

Open. Curious. Thoughtful. Human.

I’m so grateful to everyone who made this possible; the wonderful INSPIRE Lab team working tirelessly behind the scenes; all speakers and contributors for sharing their expertise and perspectives; for supporting these important conversations; team , and everyone who joined us and helped create such a warm, engaged, and reflective space.

There were many important discussions throughout the day, but to highlight a few:

🪑 Patients are often invited to share their experiences, but not always truly included in decision-making. Those are not the same thing.

💉 Insulin is far more complex than many people realise. What happens in real life (heat, travel, opened pens, everyday use, life happening) doesn’t always fit neatly into controlled conditions or protocols.

👩 Women are still too often adapting themselves to technology, instead of technology adapting to real life. Menstrual cycles and hormonal changes continue to be underrepresented in diabetes tools and algorithms.

🌍 And access to diabetes care remains deeply unequal around the world. The daily burden carried by people living with diabetes still isn’t matched by the attention, funding, or urgency it deserves.

The conference reminded me once again that insulin is never “just” a scientific topic. It’s deeply personal, emotional, practical, political.
Certainly it’s about trust, safety, equity, and quality of life.

I’m very grateful to have co-hosted and moderated this day. 🙏 I’m very hopeful about what becomes possible when science, lived experience, industry, healthcare, and advocacy genuinely come together around the same table.

Let’s keep the conversation going 💙

04/05/2026

So grateful for the opportunity to teach at today and spend time with such engaged staff and students. 🤩

We explored lived experience and what diabetes really means in daily life, beyond numbers and theory, into the real, messy, human context.

As always, the topic could easily fill much more time than we had, but it sparked a very thoughtful discussion that I truly valued.

Moments like these are a meaningful way to , sharing experience, learning from each other, and hopefully shifting perspectives just a little.

24/04/2026

📏 Your waist might be saying more about your heart ♥️ than your weight ever did…

A new long-term study (19 year!) in journal Diabetes Care looked at people with type 1 diabetes for 19 years, and found something interesting:

It’s not necessarily about how much you weigh.
👉 It’s rather where you carry it.

The key metric used in the study? Waist-to-height ratio (WHtR).

Here’s what’s up:
• A WHtR ≥ 0.5 = higher risk zone
• People in this range had ~2–3x higher risk of coronary artery disease over time
• Risk increased stepwise (every small increase in ratio mattered)
• Even people without kidney disease (often seen as “lower risk”) were affected!

So, you can have a “normal BMI”, and still carry higher cardiovascular risk.

Why this matters (especially in T1D):
👉🏼 Central fat (around your organs) is metabolically active → drives inflammation → impacts heart health.

And the simplest takeaway?
Keep your waist circumference less than half your height.

No fancy tech. Just a tape measure and awareness. Sometimes the most powerful health signals are the simplest ones. 💪🏼

19/04/2026

To mark European Patients’ Rights Day, VIA Diabetes asked me to share a few thoughts on patients right and what they mean to me.

What are your thoughts? 🤔

Thank you to team VIA Diabetes! 🙏

04/04/2026

Not my comfort zone. But really bot that far from it either.

Yet, just enough to notice things feel different.

Different language. Different pace. The same life that is just lived a little wider. And even if we all know that diabetes loves routines ❣️ it’s good to get out of them sometimes, too. 🙏

Turns out you don’t need a big leap to change your perspective.

Just a small step you almost talked yourself out of. 👀

Madrid, I like this version.

26/03/2026

FROM DETECTION → CURE: the future of diabetes is being built NOW 🚀

At the IDF Europe Symposium at ATTD 2026 in Barcelona, the message was that we already have the tools. What we need now is ACTION. 🔥

Some takeaways:

👉🏼 Early detection changes everything
Up to ~40% of people are still diagnosed in DKA, with serious consequences (brain swelling, kidney injury, long-term cognitive impact).

Screening = earlier diagnosis, fewer emergencies, better outcomes.

👉🏼 Lived experience matters
Data alone isn’t enough. Emotional and psychological support must be part of care, already from day 1.

👉🏼 Prediabetes ≠ “mild”
It carries a real cardiovascular risk.
But here’s the hopeful part: remission is possible.

👉🏼 Technology as a behavior change tool
CGM isn’t just for insulin users.
It’s a real-time mirror of how food and movement impact your body → driving awareness, motivation, and healthier choices.

👉🏼 Policy can’t wait
Equity. Registries. Education. Evaluation. Participation.
We don’t need more vision statements. We need implementation. 💪🏼

👉🏼 The “Safe Hearts Plan” = prevention + early detection + long-term care. A promising roadmap we should already be acting on. 👀

✨ So, my biggest takeaway is that we are no longer talking about if we can change outcomes in diabetes, but how fast we’re willing to act.

The moment is now. ⏳

20/03/2026

Being able to attend conferences like is amazing for several reasons - networking with peers, hearing the latest & greatest in research, exploring the exhibition space, along with enjoying local cuisine ( 😋), new destinations and insights. To name a few. 👀

Yet, it’s always all about the people. 🫶🏼 Meeting known and not-yet-known friends, sharing, laughing, discussing, collaborating… Friendship. Community. Belonging. 💙

Gracias Barcelona for reminding me. 🙏 ✨

17/03/2026

🚨 ATTD 2026 Takeaway 1 (yes, here they come!! 🤩🤪)

Type 1 Diabetes is no longer something we wait for, we can find it early.

At the session “Screening and Treatment Options for Delaying Onset of Type 1 Diabetes” at ATTD 2026, one message was super clear:

👉 Screening for type 1 diabetes is no longer just research. It’s becoming reality.

Here’s what I took away:

🔬 Early detection is the goal
The clinical target is now Stage 2 T1D, before symptoms, before crisis.

⏳ Timing matters
Intervention only starts once dysglycaemia appears (but identifying risk earlier changes everything!).

❤️ Early diagnosis can:
• reduce morbidity & mortality
• prevent life-threatening complications at onset (DKA)
• give people and families time to prepare

🧠 Screening helps us to:
• map the natural history of pre-T1D
• better understand immunopathogenesis
• identify candidates for prevention trials

🌍 The burden of T1D is rising fast, with prevalence in the U.S. projected to reach 5 million by 2050, alongside significant healthcare costs and reduced life expectancy.

⚙️ To make screening scalable, we need:
• smart clinical workflows
• sustainable funding models
• strong network support

💡 My reflection is that we are shifting from reacting to type 1 diabetes → predicting and potentially delaying it.

That’s a fundamental change in how we think about this condition. 💡

16/02/2026

🧬 Stem cells & diabetes — where are we really?

A 2026 review in Diabetes & Metabolism looked at the major clinical trials investigating stem cell–based therapies for diabetes. This is a fast-paced field! 🚀

In summary: 🤓

✨ The goal: Restore insulin production or protect remaining beta cells. To move beyond lifelong insulin therapy. 🎯

🔬 Main approaches:
• Embryonic & induced pluripotent stem cells (iPSCs) → turned into insulin-producing cells and transplanted
• Mesenchymal stem cells (MSCs) → don’t make insulin, but may reduce inflammation and support beta cells
• Encapsulation devices → aim to protect transplanted cells from immune attack (without lifelong immunosuppression)

🚀 Big developments:
• Programs like Vertex’s VX-880 (zimislecel) have shown restored insulin production and major reductions in insulin needs in early trials.
• Some participants have achieved insulin independence (but most approaches still require immunosuppression).
• Autologous (derived from the person) stem cell strategies are emerging.

⚠️ Remaining challenges:
• Immune rejection
• Need for immunosuppression
• Long-term safety (tumor risk)
• Device durability & vascularization
• Scalability & cost

📌 Bottom line:
Stem cell therapy for diabetes is no longer science fiction. It’s clinically real, but still quite far from routine care. The next few years will be critical.

For those of us living with type 1 diabetes, this is one of the most closely watched frontiers in medicine. 👀

Adresse

Zürich

Webseite

https://hannaboethius.com/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von Hanna Diabetes Expert erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.